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Available online 2 March 2017Background: Detection and treatment of heart failure (HF) can improve quality of life and reduce premature
mortality. However, symptoms such as breathlessness are common in primary care, have a variety of causes
and not all patients require cardiac imaging. In systems where healthcare resources are limited, ensuring those
patients who are likely to have HF undergo appropriate and timely investigation is vital.
Design: A decision tree was developed to assess the cost-effectiveness of using the MICE (Male, Infarction,
Crepitations, Edema) decision rule compared to other diagnostic strategies to identify HF patients presenting
to primary care.
Methods: Data from REFER (REFer for EchocaRdiogram), a HF diagnostic accuracy study, was used to determine
which patients received the correct diagnosis decision. The model adopted a UK National Health Service (NHS)
perspective.
Results: The current recommended National Institute for Health and Care Excellence (NICE) guidelines for
identifying patients with HF was the most cost-effective option with a cost of £4400 per quality adjusted life
year (QALY) gained compared to a “do nothing” strategy. That is, patients presenting with symptoms suggestive
of HF should be referred straight for echocardiography if they had a history of myocardial infarction or if
their NT-proBNP level was ≥400 pg/ml. The MICE rule was more expensive and less effective than the other
comparators. Base-case results were robust to sensitivity analyses.
Conclusions: This represents the ﬁrst cost-utility analysis comparing HF diagnostic strategies for symptomatic
patients. Current guidelines in Englandwere themost cost-effective option for identifying patients for conﬁrmatory
HF diagnosis. The low number of HF with Reduced Ejection Fraction patients (12%) in the REFER patient population
limited the beneﬁts of early detection.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Heart failure (HF) is a common clinical conditionwhich is associated
with major impact for patients and high costs for health systems, but is
not easy to diagnose accurately or early in primary care [1–3].
The main symptoms suggestive of HF are shortness of breath, tired-
ness and swollen ankles but these complaints are common in primary
care and most patients presenting with them will not have HF [4].
Furthermore, referring all symptomatic patients on for conﬁrmatory
investigations, such as echocardiography, is expensive. However, early
detection of HF is important since evidence-based therapies can
substantially improve quality of life, reduce premature mortality, ande under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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effective strategy for diagnosing HF patients at primary care level
is not known.
There is a paucity of data on diagnostic strategies in patients
presenting in primary care with symptoms suggestive of HF where
the population are rigorously phenotyped for HF. Economic analyses
of diagnostic triage for this patient population are rarer still, but the
REFER (REFer for EchocaRdiogram) study provides appropriate data to
undertake an economic evaluation.
REFER [7] was a prospective, observational, diagnostic validation
study of the MICE (Male, Infarction, Crepitations, Edema) clinical
decision rule–with natriuretic peptide testing–for diagnosing HF in pri-
mary care. The full methods for the study have been previously published
elsewhere [8]. The clinical decision rulewas developed froman Individual
Patient Databasemeta-analysis of epidemiological studies of HF screening
in primary care [9].
Brieﬂy, primary care patients aged 55 years or over presenting
to their GP with symptoms suggestive of HF were recruited across
28 Central England practices in the UK. All consenting patients
underwent a full clinical assessment, which included a NT-pro
B-type natriuretic peptide (NT-proBNP) test, an echocardiogram
and quality of life questionnaire, at a research clinic within one
week of recruitment. Follow-up quality of life and resource
use questionnaires were mailed to the patients at six and twelve
months after attending the clinic.
The 304 patients included in the REFER study had the following
characteristics: mean age of 73.9 years, White ethnicity (70.4%), male
(40.8%), history of myocardial infarction (11.2%), basal crepitations
(5.3%), ankle oedema (81.6%), lethargy (74.3%) and had a median
NT-proBNP of 214 pg/ml (IQR 79 pg/ml–494 pg/ml).
The diagnosis of ‘heart failure’ or ‘no heart failure’ was determined
by an expert panel of cardiologists using the European Society of
Cardiology (ESC) 2012 deﬁnition [5]. Clinical information, including
the variables of the MICE rule and NT-proBNP level, was presented in
stages to quantify any incorporation bias.
The aimof this studywas to assess the cost-effectiveness of using the
MICE clinical decision rule inHF diagnosis in Primary Care fromaNational
Health Service (NHS) and Personal Social Services perspective. To do so, a
decision tree was developed comparing different diagnostic strategies
against the clinical decision rule. The economic analysis utilized the
REFER dataset to determine which symptomatic patients received
the correct diagnosis decision. The economic evaluation took a lifetime
horizon and all costs and outcomes were discounted at an annual rate
of 3.5% as recommended by the National Institute of Health and Care
Excellence (NICE) [10].
2. Methods
The six comparators are described below. Since the MICE rule has
lower and upper cut-offs for the NT-proBNP referral levels, we treated
themas two different diagnostic comparators:MICEupper cut-off levels
andMICE lower cut-off levels. Strategies differed in terms of immediate
actions. All patients with true HF who were not referred at this stage
were assumed to return six months later and such patients will be
referred immediately for echocardiography.
2.1. Economic evaluation diagnostic pathways
2.1.1. MICE clinical decision rule
The MICE clinical decision rule states a patient presenting with HF
symptoms at the GP will be referred straight for echocardiography if
the patient has either a history of myocardial infarction (MI), or basal
crepitations, or is a male with ankle oedema. Otherwise a NT-proBNP
test is carried out and the patient is referred straight for echocardiography
if the test results are above one of three cut-offs set by gender/symptomsrecorded in the clinical rule (where the upper MICE NT-proBNP cut-off
levels are in parentheses):
• A female patient without ankle oedema should be referred if
NT-proBNP is ≥620 pg/ml (1060 pg/ml),or
• Amale patientwithout ankle oedema should be referred if NT-proBNP
is ≥390 pg/ml (660 pg/ml),or
• A female patient with ankle oedema should be referred if NT-proBNP
is ≥190 pg/ml (520 pg/ml)
2.2. NICE recommended strategy
NICE guidelines for the management of chronic HF6 suggest that a
patient presenting with symptoms suggestive of HF should be referred
straight for echocardiography if they have a history of MI. Otherwise a
NT-proBNP test should be carried out and patient referred for an
echocardiograph if the NT-proBNP level is ≥400 pg/ml.
2.3. Echo all strategy
With the echo all strategy, all patients presentingwith HF symptoms
at the GP will be referred straight for echocardiography. We make a
simplifying assumption that there will be no problems with access to
echocardiography.
2.4. NT-proBNP 125 strategy
With the NT-proBNP 125 strategy, all patients presenting with HF
symptoms at the GP will have a NT-proBNP test carried out and the
patient is referred for echocardiography if their NT-proBNP level
is ≥125 pg/ml.
2.5. Do nothing strategy
With the do nothing strategy, no patients presenting with HF symp-
toms at theGPwill be referred straight for echocardiography nor undergo
a NT-proBNP test. This option was added in for completeness.
A decision tree, presented in TreeAgePro 2014 (TreeAge Software,
Williamstown,MA) and developed in Excel, was structured to represent
the various diagnostic strategies (Fig. 1). A decision tree was appropri-
ate here as the comparators diverge with regard to immediate actions.
Branch probabilities were estimated from the REFER dataset. To ensure
correct representation of the statistical uncertainty in the model, pa-
tientswere categorised into groups (Appendix Table 1), on the principle
that two patients would be in the same group if and only if they follow
the same pathway in all strategies considered. For example, consider
four patients of the same sex and with the same clinical signs, with no
previous MI, but with NT-proBNP at 110 pg/ml (A), 220 pg/ml (B),
330 pg/ml (C), and 440 pg/ml (D). Under the “NT-proBNP125” strategy,
patients B, C andDwould be referred for echocardiography, but Awould
not, while under the NICE strategy, only patient D would be referred.
However, no strategy in the model has a cut-off between 220 pg/ml
and 330 pg/ml, so patients B and C can be in the same group.
The methodology behind the beneﬁts of each strategy was drawn
largely from a previous HF Health Technology Assessment (HTA) report
[9]. We assumed a conﬁrmed HF diagnosis leads to patients being
initiated on HF drug treatment if they have HF with Reduced Ejection
Fraction (HFREF). Current trials do not suggest a survival advantage of
angiotensin converting-enzyme inhibitors (ACEIs) or beta-blockers for
HF patients with preserved ejection fraction (HFPEF) [11]. Thus, the
beneﬁts from early detection of HF were weighted by the number
of HF patients in the population (12%) that have a reduced ejection
fraction.
The type of HF drug and dose was obtained from a cohort study of
patients treated for HF in primary care; 36.6% of patients were treated
with beta-blockers, 58.9% of patients were treated with ACEIs, and
Fig. 1. Decision tree of the different diagnostic strategies for patients presenting with heart failure symptoms in primary care.
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(ARBs) [12]. Patients can be on more than one HF drug therapy; to de-
termine the proportion of patients on ACEI but not on beta-blockers
(not reported), we took a simple average of upper bound and lower
bound range of the possible values (36.3%).
HF treatment initiation due to correct early detection was assumed
to have a survival beneﬁt for the HF patient versus a missed HF diagno-
sis. A missed HF diagnosis was assumed to delay the diagnosis by six
months. Delayed diagnosis patients were assumed to incur a further
GP visit and an echocardiogram to conﬁrm the diagnosis. After six
months, the patient was put on treatment and thereafter has the same
survival probability as someone who was already on treatment.
We took the survival data from diagnosis of HF in patients in the
Framingham heart study [13] to be the patient's prognosis without
drug therapy. A meta-analysis indicated that beta-blockers versus pla-
cebo gave a hazard ratio of 0.73 (95% conﬁdence interval 0.67–0.80)
for all-cause mortality, 95% of these beta-blockers patients were also
on ACEI/ARBs [14]. The results of a systematic review showed that the
mortality odds ratio for patients taking ACEI compared to a placebo
was 0.80 (95% conﬁdence interval 0.74–0.87) [15]. A Cochrane review
found no signiﬁcant effect of ARBs on mortality and, therefore, we
make a conservative assumption that patients on ARBs only have the
same survival rate as untreated patients [16].
Survival data and drug efﬁcacies were used to plot gender-speciﬁc
survival curves for the untreated patients and patients on different
drug therapies (assuming no temporal changes in drug efﬁcacy). The
curves were extended beyond the ten year survival data via linear
extrapolation to achieve a lifetime horizon. Patients who were put on
treatment earlier due to correct detection (Treat early) and patients
with a delayed diagnosis (Treat late) were weighted by the proportion
of patients on the different drug therapies. Survival beneﬁt due to
early treatment was the area between the treated early and treated
late curves.
Patients with HF in the REFER study that answered the six months
follow-up questionnaire, scored with UK tariffs [17], gave an average
EuroQol 5 dimensions (EQ-5D) score of 0.615 (standard deviation of
0.31). Discounted quality adjusted life year gain can be estimated from
the product of the EQ-5D and the discounted life years gained.Early detection of HF also has the beneﬁt of a reduction in hospital-
izations. Patients on beta-blockers versus placebo have a hazard ratio
of 0.71 (95% CI 0.65–0.77) for ﬁrst HF related hospital admission [14].
Similarly, treatment with ACEIs reduces the likelihood of a hospital
admission with an odds ratio of 0.67 (95% CI 0.61–0.74) [15].
For model purposes, we were interested in the increased rate of
admission into hospital for an untreated population due to a six
month delay in a HF diagnosis. Firstly, we take a previously calculated
probability of admission if treated of 41.3% [9]. Using the odds ratio of
hospital admission with ACEI treatment, the rate of admission within
six months if untreated is 0.62. Assuming a constant hazard ratio for
treatmentwith beta-blockers over the sixmonths, the rate of admission
within six months if untreated is 71.2%. A simple average was taken to
calculate the estimated rate of admission with six months if untreated
(66.4%). Thus, the increased number of hospitalization cases if untreated
is 25.1%. This was then weighted by the number of HFREF patients in
the population as only these patients receive prognostic beneﬁt from
treatment.
Costs were inﬂated to 2013/2014 prices using the hospital & commu-
nity health service (HCHS) pay and prices index where applicable [18].
The cost of a General Practitioner appointment (£46) was taken from
Unit Costs [18]. The cost of an avoidable HF hospital admissionwas calcu-
lated from weighted average reference costs of HF admissions (£2107)
[19]. An echocardiography referral cost was taken from the Payment by
Results mandatory tariff [20], consisting of a simple echocardiogram and
a consultant-led outpatient ﬁrst attendance (totalling £241). The cost of
a NT-proBNP test (£30) was taken from a NICE costing report [21].
The early treatment HF drug cost was estimated from the resource
usage combined with prices from the British National Formulary
(BNF) [22]. Since the typical drug dose for a HF patient is variable, we
pragmatically assumed that same percentage of patients reach the tar-
get dose–as deﬁned by the 2005 ESC guidelines in their study–and the
remainder achieve half the target dose. Where the drug listed was not
recommended by the 2012 ESC guidelines [5], the target dose indication
for HF in the BNF was used. For the base-case analysis, the cost of the
generic drugs for the ﬁrst six months was used (£10); the cost of the
equivalent therapywith branded drugswas substituted for the sensitiv-
ity analysis (£30).
Table 1
Parameter distributions for probabilistic sensitivity analysis.
Parameters Distribution Parameter estimatesa Deterministic valueb Source
Patients true diagnosis Beta α = 104 34.2% REFER dataset [7]
β = 200
Heart failure utility (EuroQol-5 dimensions) Beta α = 0.95 0.62 REFER dataset [7]
β = 0.59
Beta-blocker effect on mortality Log normal μ = −0.31 0.73 Kotecha and colleagues [14]
σ = 0.05
Beta-blocker effect on hospitalization risk Log normal μ = −0.34 0.71 Kotecha and colleagues [14]
σ = 0.04
ACEI effect on mortality Log normal μ = −0.22 0.80 Flather and colleagues [15]
σ = 0.04
ACEI effect on hospitalization risk Log normal μ = −0.40 0.67 Flather and colleagues [15]
σ = 0.05
Patients on each drug therapy (beta-blockers, ACEI, other) Dirichlet (α1,α2,α3) = (3403,3378,1908) (36.5%,36.3%,6.1%) Calvert and colleagues [12]
ACEI, angiotensin converting-enzyme inhibitors.
a For the lognormal distributions, μ is the mean and σ is the standard deviation of the underlying normal distribution which gives the logarithm of the model parameter.
b The deterministic value is the mean except in the case of the lognormal distributions where the median is given.
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ordered by increasing cost. Effectiveness was measured in quality
adjusted life years (QALYs). The incremental analysis was designed to
generate the cost per additional QALY gained for using one diagnostic
strategy over another. Cost-effectiveness was assessed in relation to the
lower NICE threshold of £20,000 per QALY gained [23]. More costly and
less effective options were excluded from consideration (dominated).
Likewise options that suffer from extended dominance were removed
from consideration. Extended dominance occurs when an option would
be dominated compared to a mixed option of two other strategies.
Sensitivity analysis was performed to assess model robustness. For
the deterministic sensitivity analysis, the following scenarios were
explored:
1. Doubling and halving the cost of a NT-proBNP test.
2. Altering the drug efﬁcacies to their lower and upper conﬁdence
intervals respectively.
3. Substituting in branded drug therapy prices for generic drug therapy
prices.
4. Increasing the proportion of HFREF patients from 12% to 24%, 50%,
and 100% respectively.
For the probabilistic sensitivity analysis, distributions were attached
to the clinical parameters, drug efﬁcacies, and HF utility (Table 1). The
model was run for 10,000 iterations and the results presented as a
cost-effectiveness acceptability frontier (CEAF). The CEAF shows, across
a range of different cost-effectiveness thresholds, the uncertainty asso-
ciated with the optimal diagnostic option.
Positive count data in patient groups formed the parameters for the
Dirichlet distribution (Appendix Table 1). On each replication a vector of
probabilities was sampled from the appropriate distribution. Where
therewas no count data (no patients) in a group, no distributionwas at-
tached. Treating the probability as ﬁxed for these empty patient groups
will slightly underestimate the uncertainty in themodel rather than the
alternative of adding anoccurrence and positively biasing the amount of
occurrences [24].Table 2
Base-case results.
Strategy Costs (£) QALY gain compared to “do nothing” Cost per Q
Do nothing 119 –
NICE strategy 142 0.0051 £4400
MICE upper cut-off 167 0.0050 (Dominat
MICE lower cut-off 191 0.0057 (Extende
NT-proBNP 125 196 0.0059 £69,000
Echo all 241 0.0063 £125,100
QALY, quality adjusted life year; HF, heart failure; NICE, National Institute for Health and Care3. Results
Costs and effectiveness of each strategy are shown in Table 2. The
clinical decision rules of MICE were dominated by the other strategies.
Given a willingness to pay (WTP) threshold of £20,000/QALY, only the
NICE strategy was cost-effective.
Sensitivity analyses (Table 3) showed that NICE strategy remained
the most cost-effective option for each scenario except where the pro-
portion of HFREF changed to 50% and above. When the proportion of
HFREF patients was 50%, the NT-proBNP 125 strategy became cost-
effective, and when this proportion reaches 100%, it became cost-
effective to refer all patients for immediate echocardiography.
Fig. 2 illustrates the overall uncertainty related to the optimal deci-
sion across a range of plausible WTP values, where WTP was measured
in cost per additional QALY. At £20,000/QALY, the likelihood of the NICE
strategy being the optimal option (i.e. highest Net Monetary Beneﬁt) is
99.9%. As theWTP threshold increases beyond £68,000, the NT-proBNP
125 option becomes more likely to be the optimal option.
4. Discussion
Results indicate that, for the REFER population, current NICE
guidelines on diagnosing HF represent the most cost-effective strategy
compared to the MICE decision rules and other diagnostic strategies.
That is, patients presenting with symptoms suggestive of HF should be
referred straight for echocardiography if they have a history of MI or if
their NT-proBNP level is ≥400 pg/ml. The MICE decision rules were
not cost-effective due to dominance by the other strategies. The cost-
effectiveness results were robust to deterministic and probabilistic
sensitivity analysis.
Modest effectiveness gains for each strategy can be largely explained
by the REFER study patient characteristics. The modelled beneﬁts of
early detection of HF and the subsequent prognostic window of im-
provement (treated early versus treated late) were limited since only
12% of the REFER HF participants were HFREF patients. We modelled
no beneﬁts from earlier detection in the 88% of the REFERHF populationALY Proportion of true HF detected Proportion of not HF ruled out
0.00% 100.00%
78.85% 63.50%
ed) 81.73% 84.00%
d dominance) 90.38% 45.50%
94.23% 49.00%
100.00% 0.00%
Excellence; cost per QALY rounded to the nearest multiple of £100/QALY.
Table 3
Deterministic sensitivity analysis scenario results.
NICE strategy versus do nothing NT-proBNP 125 versus NICE strategy Echo all versus NT-proBNP 125
Scenarioa Cost per additional quality adjusted life year (QALY)
Base case results £4400 £69,000 £125,100
Double NT-proBNP test cost £9600 £73,300 £42,100
Half NT-proBNP cost £1800 £66,800 £166,600
Branded drug price therapy £9700 £68,900 £125,200
Higher drug efﬁcacy for mortality £3300 £52,000 £94,200
Lower drug efﬁcacy for mortality £6600 £104,200 £189,100
Proportion of HFREF patients doubled to 24% £600 £32,900 £60,900
Proportion of HFREF patients increased to 50% Dominates do nothing £13,300 £26,400
Proportion of HFREF patients increased to 100% Dominates do nothing £5000 £11,600
NICE, National Institute for Health and Care Excellence; HFREF, Heart Failure with Reduced Ejection Fraction; cost per QALY rounded to the nearest multiple of £100/QALY.
a The MICE cut-off options were excluded from the table as they remain dominated in each scenario.
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ment but it is unlikely that these patients will derive zero beneﬁt from
detection. Although drug trials in HFPEF have failed to prove prognostic
beneﬁt, there is still a need for diagnosis to allow clinicians to explain
and manage patient symptoms, and for ongoing research to ﬁnd novel
approaches to HFPEF treatment.
Increasing the proportion of HREF patients raised the total QALYs of
each diagnostic strategy due to the higher rewards of a correct early
detection. Most population surveys suggest that approximately half of
HF patients suffer HFREF, in contrast to the 12% detected in REFER,
and in this sensitivity scenario the dominant cost-effective strategy is
the reduced NT-proBNP cut-off for referral for echocardiography of
125 pg/ml rather than the NICE level of 400 pg/ml. Echo all strategy be-
came the most cost-effective option when we assume all the HF patients
will receive prognostic beneﬁt from treatment. However, it must be ac-
knowledged that there may be practical barriers to the implementation
of such a strategy. Delays to echocardiograms may potentially offset the
advantage of early detection and referring all patients for an echocardio-
gram will put pressure on local diagnostic services.
Since NT-proBNP came into more general use in the healthcare
system, the costs per test may have dropped so the cost-effectiveness of
natriuretic peptide testing may be underestimated here. Halving the
cost of a NT-proBNP test made the NT-proBNP strategies more cost-
effective compared with the ‘echo all’ and the ‘do nothing’ strategies.
HF therapy drug mix related to a 2009 publication from older data
[12]. As it is likely that there are higher drug rates nowadays, the as-
sumed proportion of patients on ACEIs and beta-blockers may be
underestimated so the beneﬁt of early diagnosis may be greater. Since
the clinical study has been carried out, guidelines on the diagnosis and
treatment of heart failure have been updated; [25] hence diagnosis ofFig. 2. Cost-effectiveness acceptability frontier showing the optimal diagnostic strategy
across a range of willingness to pay thresholds.HF is according to 2012 deﬁnitions and HF with Mid-Range Ejection
Fraction was not considered as a third group as in the 2016 guidelines.
This is the ﬁrst cost utility analysis to compare a representative range
of strategies for diagnosis in this patient population, making comparison
to other studies difﬁcult. Previous studies [26,27] have looked at the
costs of using NT-proBNP as a means to rule out HF and to reduce
the levels of echocardiography referrals but these cannot address the
question of an optimal cost-effective diagnostic strategy and also did
not place a cost on a missed HF diagnosis.
Themain strength of this analysis is that the diagnostic accuracy of the
various strategies tested was calculated based on a consistent primary
dataset. Thiswas reinforced by theprocess used in the clinical study tode-
velop an appropriate gold standard against which to compare imperfect
diagnostic strategies. The main limitations are that the REFER dataset
may not be typical of patients in other geographic areas, and the need
for assumptions in projecting the lifetime costs and outcomes from cor-
rect diagnosis. The low prevalence of HFREF in the REFER patient popula-
tion may be due to patients with HFREF being more likely to present
themselves directly to secondary care rather than primary care [7]. The
lack of representation of HFREF patients compared with other studies
may represent a selection bias affecting the ﬁnal results.
Overall, this analysis provides evidence based on primary data that
the current strategy recommended by NICE is appropriate. However,
based on sensitivity analyses, as the proportion of HFREF increases
from the 12% seen in REFER, it becomes more cost-effective to change
the NICE NT-proBNP threshold from 400 pg/ml to 125 pg/ml.
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REFER patient characteristics.Clinical parameters n (%)
Heart failure
(n = 104)No heart failure
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atients with previous MI with NT-proBNP levels greater than or equal to 125 pg/ml 16 (15.4) 7 (3.5)
atients with basal crepitations without previous MI with NT-proBNP levels b125 pg/ml 0 (0.0) 5 (2.5)
atients with basal crepitations without previous MI with NT-proBNP levels between 125 pg/ml and 399 pg/ml 0 (0.0) 4 (2.0)
atients with basal crepitations without previous MI with NT-proBNP levels equal to or above 400 pg/ml 3 (2.9) 2 (1.0)
ale patients with ankle oedema without basal crepitations or previous MI with NT-proBNP b125 pg/ml 0 (0.0) 22 (11.0)
ale patients with ankle oedema without basal crepitations or previous MI with NT-proBNP levels between 125 pg/ml and 399 pg/ml 4 (3.8) 17 (8.5)
ale patients with ankle oedema without basal crepitations or previous MI with NT-proBNP levels equal to or above 400 pg/ml 22 (21.2) 5(2.5)
male patients without ankle oedema without the MICE criteria with NT-proBNP levels b125 pg/ml 0 (0.0) 9 (4.5)
male patients without ankle oedema without the MICE criteria with NT-proBNP levels between 125 pg/ml and 399 pg/ml 0 (0.0) 6 (3.0)
male patients without ankle oedema without the MICE criteria with NT-proBNP levels between 400 pg/ml and 619 pg/ml 0 (0.0) 2 (1.0)
male patients without ankle oedema without the MICE criteria with NT-proBNP levels between 620 pg/ml and 1059 pg/ml 1 (1.0) 0 (0.0)
male patients without ankle oedema without the MICE criteria with NT-proBNP levels equal to or above 1060 pg/ml 0 (0.0) 0 (0.0)
male patients with ankle oedema without the MICE criteria with NT-proBNP levels b125 pg/ml 4 (3.8) 43 (21.5)
male patients with ankle oedema without the MICE criteria with NT-proBNP levels between 125 pg/ml and 189 pg/ml 3 (2.9) 15 (6.5)
male patients with ankle oedema without the MICE criteria with NT-proBNP levels between 190 pg/ml and 399 pg/ml 4 (3.8) 31 (15.5)
male patients with ankle oedema without the MICE criteria with NT-proBNP levels between 400 pg/ml and 519 pg/ml 4 (3.8) 5 (2.5)
male patients with ankle oedema without the MICE criteria with NT-proBNP levels equal to or above 520 pg/ml 30 (28.8) 0 (0.0)
ale patients without ankle oedema without the MICE criteria with NT-proBNP levels b125 pg/ml 1 (1.0) 9 (4.5)
ale patients without ankle oedema without the MICE criteria with NT-proBNP levels between 125 pg/ml and 389 pg/ml 2 (2.0) 7 (3.5)
ale patients without ankle oedema without the MICE criteria with NT-proBNP levels between 390 pg/ml and 399 pg/ml 1 (1.0) 0 (0.0)
ale patients without ankle oedema without the MICE criteria with NT-proBNP levels between 400 pg/ml and 659 pg/ml 2 (2.0) 0 (0.0)
ale patients without ankle oedema without the MICE criteria with NT-proBNP equal to or above 660 pg/ml 6 (5.8) 1 (0.50)MMI, myocardial infarction.Appendix Table 2
Estimated undiscounted survival probabilities for male patients with heart failure on and off therapy.Years Untreated ACEI BB Treated early Treated late1.00 1.00 1.00 1.00 1.00
.25 0.73 0.77 0.79 0.77 0.73
.5 0.68 0.72 0.75 0.72 0.680.57 0.62 0.66 0.62 0.59
0.46 0.52 0.57 0.52 0.49
0.25 0.29 0.36 0.31 0.290 0.11 0.13 0.20 0.15 0.14
1 0.08 0.10 0.16 0.12 0.11
2 0.05 0.07 0.12 0.08 0.07
3 0.03 0.03 0.07 0.04 0.04
4 0.00 0.00 0.02 0.01 0.00
5 0.00 0.00 0.00 0.00 0.001
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Estimated undiscounted survival probabilities for female patients with heart failure on and off therapyYears0
0
0
1
2
5
1
1
1
1
1
1
1Untreated ACEI BB Treated early Treated late1.00 1.00 1.00 1.00 1.00
.25 0.72 0.76 0.79 0.76 0.72
.5 0.69 0.74 0.77 0.74 0.690.64 0.69 0.72 0.69 0.65
0.56 0.61 0.65 0.61 0.58
0.38 0.43 0.49 0.44 0.410 0.21 0.25 0.32 0.26 0.25
1 0.18 0.21 0.28 0.23 0.21
2 0.14 0.17 0.24 0.19 0.17
3 0.11 0.13 0.20 0.15 0.14
4 0.07 0.09 0.15 0.11 0.10
5 0.04 0.05 0.10 0.06 0.06
6 0.01 0.01 0.02 0.01 0.01
7 0.00 0.00 0.00 0.00 0.001References
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